Vascepa, a prescription medication used to treat high levels of triglycerides in the blood, has been a popular drug in the United States. However, the patent for Vascepa expired in 2020, and since then, several pharmaceutical companies have been working to produce generic versions of the drug. According to Drug Patent Watch [1], the first generic version of Vascepa was approved by the FDA in December 2020. The approval was granted to Dr. Reddy's Laboratories, a multinational pharmaceutical company based in India. This approval allows Dr. Reddy's Laboratories to produce and sell a generic version of Vascepa in the United States.

It is important to note that Amarin, the company that developed Vascepa, lost a patent appeal in 2020 [2]. This means that other pharmaceutical companies can produce generic versions of Vascepa without infringing on Amarin's patent rights. In addition to Dr. Reddy's Laboratories, several other companies are also working on producing generic versions of Vascepa, including Hikma Pharmaceuticals and Teva Pharmaceuticals [2].

It is not yet clear when these other generic versions of Vascepa will be available on the market. However, according to Formulary Watch [3], Prime Therapeutics, a pharmacy benefit manager, has removed Vascepa from its Medicare formularies and replaced it with the generic version produced by Dr. Reddy's Laboratories. This suggests that the generic version of Vascepa produced by Dr. Reddy's Laboratories is already available for purchase in some parts of the United States.

In conclusion, the first generic version of Vascepa was approved by the FDA in December 2020 and is currently being produced and sold by Dr. Reddy's Laboratories. Other pharmaceutical companies, including Hikma Pharmaceuticals and Teva Pharmaceuticals, are also working on producing generic versions of Vascepa, but it is not yet clear when these versions will be available on the market [1][2]. However, it appears that the generic version produced by Dr. Reddy's Laboratories is already available for purchase in some parts of the United States [3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.fiercepharma.com/marketing/it-s-confirmed-amarin-loses-patent-appeal-protecting-blockbuster-hopeful-vascepa-from
[3] https://www.formularywatch.com/view/prime-therapeutics-two-drugs-from-medicare-formularies